Concepedia

Olga Valota

OV

Statistics

Publications

24

Citations

1.2K

H-Index

16

Active since

1995

Affiliations

Pfizer (Italy)(Current)

Pfizer (United States)

Memorial Sloan Kettering Cancer Center

Fudan University Shanghai Cancer Center

University of Ulsan

Olga Valota is an author at Pfizer (Italy) specializing in oncology, medicine, and pharmacology.

Publications per year

1995–2025

24

Publications

24

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Mark R. Olsen et al. · Journal of Clinical Oncology · 2012 · 275 citations · Full text

Medicine, Oncology, Pharmacology +17

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

Marine Gross‐Goupil, Tae‐Geon Kwon, Masatoshi Eto et al. · Annals of Oncology · 2018 · 257 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma

Yoon‐Koo Kang, Thomas Yau, J.-W. Park et al. · Annals of Oncology · 2015 · 104 citations · Full text

Medicine, Oncology, Pharmacology +11

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer

Mario Campone, Michelino De Laurentiis, Komal Jhaveri et al. · New England Journal of Medicine · 2025 · 94 citations

Medicine, Oncology, Pharmacology +17

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

Robert J. Motzer, Thomas E. Hutson, Gary R. Hudes et al. · Cancer Chemotherapy and Pharmacology · 2014 · 74 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

1–5 of 24